{"id":50714,"date":"2025-12-14T20:54:35","date_gmt":"2025-12-14T12:54:35","guid":{"rendered":"https:\/\/flcube.com\/?p=50714"},"modified":"2025-12-14T20:54:37","modified_gmt":"2025-12-14T12:54:37","slug":"indupro-secures-sanofi-investment-and-first-negotiation-rights-on-pd-1-agonist-program","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50714","title":{"rendered":"InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program"},"content":{"rendered":"\n<p><strong>InduPro Therapeutics<\/strong>, a biotechnology company defining membrane protein spatial relationships for novel therapeutics, announced a strategic equity investment and research collaboration with <strong>Sanofi<\/strong>. The agreement grants Sanofi <strong>right of first negotiation<\/strong> for InduPro\u2019s <strong>bispecific PD-1 agonist program<\/strong>, currently in preclinical development for autoimmune and inflammatory disorders. Sanofi will fund preclinical and IND\u2011enabling activities while making an <strong>undisclosed equity investment<\/strong> in InduPro.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Equity Investment<\/strong><\/td><td>Undisclosed amount from Sanofi into InduPro<\/td><\/tr><tr><td><strong>Research Funding<\/strong><\/td><td>Sanofi to fund preclinical and IND\u2011enabling activities<\/td><\/tr><tr><td><strong>Right of First Negotiation<\/strong><\/td><td>Sanofi receives first rights on the PD-1 agonist program<\/td><\/tr><tr><td><strong>Collaboration Scope<\/strong><\/td><td>Preclinical research on bispecific PD-1 agonist for autoimmune diseases<\/td><\/tr><tr><td><strong>Stage<\/strong><\/td><td>Preclinical development<\/td><\/tr><tr><td><strong>Potential Expansion<\/strong><\/td><td>May extend to additional R&amp;D projects as needed by both parties<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform\">Technology Platform<\/h2>\n\n\n\n<p>InduPro\u2019s proprietary discovery engine leverages <strong>high\u2011resolution proximity labeling technology<\/strong> to map protein neighborhoods on cell surfaces, identifying <strong>novel co\u2011target pairs<\/strong> highly selective for specific disease biology. By targeting these unique pairings via <strong>induced proximity<\/strong>, the platform generates potential <strong>first\u2011in\u2011class and best\u2011in\u2011class<\/strong> therapeutic candidates across <strong>cancer and autoimmune diseases<\/strong>. The PD-1 agonist program exemplifies this approach, creating bispecific molecules that modulate immune signaling through precise spatial control.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For InduPro:<\/strong> Sanofi\u2019s investment validates the <strong>proximity technology platform<\/strong>; provides <strong>non\u2011dilutive capital<\/strong> to advance the PD-1 agonist toward IND; Sanofi\u2019s expertise in immunology accelerates development.<\/li>\n\n\n\n<li><strong>For Sanofi:<\/strong> Secures early access to a <strong>novel bispecific PD-1 agonist<\/strong> with potential in <strong>autoimmune and inflammatory disorders<\/strong>; right of first negotiation de\u2011risks future acquisition; expands immuno\u2011oncology portfolio into autoimmunity.<\/li>\n\n\n\n<li><strong>Market Context:<\/strong> Global autoimmune disease market exceeds <strong>$150\u202fbillion<\/strong>; PD-1 agonists represent an emerging class with potential in <strong>lupus, inflammatory bowel disease, and multiple sclerosis<\/strong> where current immunosuppressants have limitations.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-status\">Pipeline Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Target<\/th><th>Indication<\/th><th>Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>PD-1 Agonist (Bispecific)<\/strong><\/td><td>PD-1 + Co\u2011target (undisclosed)<\/td><td>Autoimmune &amp; inflammatory disorders<\/td><td>Preclinical<\/td><\/tr><tr><td><strong>Oncology Programs<\/strong><\/td><td>Multiple co\u2011target pairs<\/td><td>Cancer<\/td><td>Discovery\/preclinical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the collaboration\u2019s development timeline, equity investment details, and the potential for additional projects. Actual results may differ due to scientific risks, regulatory challenges, or changes in strategic priorities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>InduPro Therapeutics, a biotechnology company defining membrane protein spatial relationships for novel therapeutics, announced a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50719,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4501,18,147],"class_list":["post-50714","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-indupro-therapeutics","tag-pd-1-l1","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"InduPro Therapeutics, a biotechnology company defining membrane protein spatial relationships for novel therapeutics, announced a strategic equity investment and research collaboration with Sanofi. The agreement grants Sanofi right of first negotiation for InduPro\u2019s bispecific PD-1 agonist program, currently in preclinical development for autoimmune and inflammatory disorders. Sanofi will fund preclinical and IND\u2011enabling activities while making an undisclosed equity investment in InduPro.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50714\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program\" \/>\n<meta property=\"og:description\" content=\"InduPro Therapeutics, a biotechnology company defining membrane protein spatial relationships for novel therapeutics, announced a strategic equity investment and research collaboration with Sanofi. The agreement grants Sanofi right of first negotiation for InduPro\u2019s bispecific PD-1 agonist program, currently in preclinical development for autoimmune and inflammatory disorders. Sanofi will fund preclinical and IND\u2011enabling activities while making an undisclosed equity investment in InduPro.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50714\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-14T12:54:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-14T12:54:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1401.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50714#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50714\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program\",\"datePublished\":\"2025-12-14T12:54:35+00:00\",\"dateModified\":\"2025-12-14T12:54:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50714\"},\"wordCount\":375,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50714#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1401.webp\",\"keywords\":[\"InduPro Therapeutics\",\"PD-1\\\/L1\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50714#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50714\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50714\",\"name\":\"InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50714#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50714#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1401.webp\",\"datePublished\":\"2025-12-14T12:54:35+00:00\",\"dateModified\":\"2025-12-14T12:54:37+00:00\",\"description\":\"InduPro Therapeutics, a biotechnology company defining membrane protein spatial relationships for novel therapeutics, announced a strategic equity investment and research collaboration with Sanofi. The agreement grants Sanofi right of first negotiation for InduPro\u2019s bispecific PD-1 agonist program, currently in preclinical development for autoimmune and inflammatory disorders. Sanofi will fund preclinical and IND\u2011enabling activities while making an undisclosed equity investment in InduPro.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50714#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50714\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50714#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1401.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1401.webp\",\"width\":1080,\"height\":608,\"caption\":\"InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50714#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program - Insight, China&#039;s Pharmaceutical Industry","description":"InduPro Therapeutics, a biotechnology company defining membrane protein spatial relationships for novel therapeutics, announced a strategic equity investment and research collaboration with Sanofi. The agreement grants Sanofi right of first negotiation for InduPro\u2019s bispecific PD-1 agonist program, currently in preclinical development for autoimmune and inflammatory disorders. Sanofi will fund preclinical and IND\u2011enabling activities while making an undisclosed equity investment in InduPro.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50714","og_locale":"en_US","og_type":"article","og_title":"InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program","og_description":"InduPro Therapeutics, a biotechnology company defining membrane protein spatial relationships for novel therapeutics, announced a strategic equity investment and research collaboration with Sanofi. The agreement grants Sanofi right of first negotiation for InduPro\u2019s bispecific PD-1 agonist program, currently in preclinical development for autoimmune and inflammatory disorders. Sanofi will fund preclinical and IND\u2011enabling activities while making an undisclosed equity investment in InduPro.","og_url":"https:\/\/flcube.com\/?p=50714","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-14T12:54:35+00:00","article_modified_time":"2025-12-14T12:54:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1401.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50714#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50714"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program","datePublished":"2025-12-14T12:54:35+00:00","dateModified":"2025-12-14T12:54:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50714"},"wordCount":375,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50714#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1401.webp","keywords":["InduPro Therapeutics","PD-1\/L1","Sanofi"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50714#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50714","url":"https:\/\/flcube.com\/?p=50714","name":"InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50714#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50714#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1401.webp","datePublished":"2025-12-14T12:54:35+00:00","dateModified":"2025-12-14T12:54:37+00:00","description":"InduPro Therapeutics, a biotechnology company defining membrane protein spatial relationships for novel therapeutics, announced a strategic equity investment and research collaboration with Sanofi. The agreement grants Sanofi right of first negotiation for InduPro\u2019s bispecific PD-1 agonist program, currently in preclinical development for autoimmune and inflammatory disorders. Sanofi will fund preclinical and IND\u2011enabling activities while making an undisclosed equity investment in InduPro.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50714#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50714"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50714#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1401.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1401.webp","width":1080,"height":608,"caption":"InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50714#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1401.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50714"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50714\/revisions"}],"predecessor-version":[{"id":50720,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50714\/revisions\/50720"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50719"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}